产品
编 号：F056212
分子式：C21H14N5NaO6S
分子量：487.42
分子式：C21H14N5NaO6S
分子量：487.42
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1177131-02-0
产品详情
生物活性：
PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
体内研究：
PHPS1 (3 mg/kg; i.p. injection; every day during the last week on the high-fat diet) renders Ldlr-/- mice less susceptible to atherosclerosis development.Animal Model:Ldlr-/- (005061) mice
Dosage:3 mg/kg
Administration:Intraperitoneal (i.p.) injection; every day during the last week on the high-fat diet.
Result:Revealed a significant decrease in atherosclerotic plaque size in the aorta compared with the other two groups.
体外研究：
PHPS1 (30 μM; 6 days) inhibits proliferation of human tumor cells. PHPS1 (5-20 μM; 5-360 minutes) inhibits Erk1/2 but not Akt and Stat3 phosphorylation in a dose-dependent manner.
PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
体内研究：
PHPS1 (3 mg/kg; i.p. injection; every day during the last week on the high-fat diet) renders Ldlr-/- mice less susceptible to atherosclerosis development.Animal Model:Ldlr-/- (005061) mice
Dosage:3 mg/kg
Administration:Intraperitoneal (i.p.) injection; every day during the last week on the high-fat diet.
Result:Revealed a significant decrease in atherosclerotic plaque size in the aorta compared with the other two groups.
体外研究：
PHPS1 (30 μM; 6 days) inhibits proliferation of human tumor cells. PHPS1 (5-20 μM; 5-360 minutes) inhibits Erk1/2 but not Akt and Stat3 phosphorylation in a dose-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备